Legend Innovation Life Science Fund announced a strategic investment commitment of up to $50 million in Mid-Atlantic BioTherapeutics (MABT), a clinical-stage biotechnology company headquartered in Pennsylvania. The partnership focuses on advancing novel therapies for anti-aging applications, including treatments for neurological diseases and cancer.
Investment Details and Timeline
The investment will support MABT's continued clinical development, research initiatives, and regulatory milestones. The first funding tranche is expected in Q3 2025, marking a new chapter of growth for the company. MABT plans to initiate a Phase 3 clinical trial for its lead viral encephalitis drug in 2026 and advance new clinical programs utilizing an AI computational chemistry/structure & fragment-based discovery and development platform.
"Our dedication to transformative healthcare innovation is reflected in this partnership with Mid-Atlantic BioTherapeutics," said Dr. Syngbum (Ben) Kim, Chairman and Founder of Legend. "MABT's scientific vision and strong leadership make them an ideal investment for our fund as we work to rapidly translate pioneering research into real-world therapies for patients in need."
AI-Driven Drug Discovery Platform
MABT was founded with the mission of fighting diseases of aging like Alzheimer's and Parkinson's diseases, and other severe neurological disorders, as well as cancer. The company utilizes groundbreaking AI technologies to accelerate the development of novel treatments that aim to increase the length and quality of life for patients.
Dr. David Horn, CEO and Founder of Mid-Atlantic BioTherapeutics, commented, "We are honored by Legend's confidence in our technology and mission. This strategic investment will enable us to accelerate our programs targeting various aspects of anti-aging. With Legend's support, we are positioned to accelerate our programs that aim to extend the length and quality of people's lives."
Strategic Partnership and Future Plans
Legend is a leading biotech investment fund that accelerates AI-driven drug innovation for anti-aging/regeneration and delivers high-value returns to investors. The fund focuses its strategic investments in Pre-IPO biotech companies ready for an exit via public listing and looks to unlock value in unique top-quality overseas companies by investing and facilitating successful U.S. public listings.
MABT also plans to seek potential public listing via IPO or reverse merger within 18 months. The investment fund is dedicated to advancing life sciences and healthcare technologies, supporting entrepreneurs in bringing innovative solutions from concept to commercialization, driving global impact in areas such as anti-aging, neuroscience, obesity, diabetes, cancer, and regenerative medicine.
Both organizations look forward to a partnership that can deliver impactful advances for patients and set new benchmarks for innovation within the biotechnology industry.
